|
|
| Type |
Poster Presentation |
| Area |
Life Chemistry |
| Room No. |
Exhibition Hall 2 |
| Time |
4월 19일 (금요일) 11:00~12:30 |
| Code |
LIFE.P-351 |
| Subject |
Identification of KDH01 via inhibition of the protein tyrosine phosphatase VHR as an anti-tumor drug |
| Authors |
Do Hwi Kim, Sang Jeon Chung1,*
Pharmacy, Sungkyunkwan University, Korea
1College of Pharmacy, SungKyunKwan University, Korea
|
| Abstract |
Protein-tyrosine phosphorylation is a reversible posttranslational modification that is essential for eukaryotic cells. The counteracting activities of protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs) regulate the level of cellular tyrosine phosphorylation. Defective or inappropriate operation of these networks leads to aberrant tyrosine phosphorylation associated with many human diseases including cancers, diabetes, and inflammatory disorders. Dual specificity protein phosphatase 3 (DUSP3, also named VHR; Vaccinia-H1 related) has been shown to negatively regulate members of the mitogen-activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38) involved in cellular proliferation and differentiation. VHR is known to be highly expressed in several cervix cancer cell lines such as Hela. In this study, KDH01 isolated from Paeonia lactiflora was identified as the inhibitor for VHR with subnanomolar Ki value. In addition, we used a cell culture system treated with KDH01 to demonstrate its specificity and possibility for anticancer drug. These results identify potential new therapeutic strategies for cancer treatment.
|
| E-mail |
rlaehgnl94@naver.com |
|
123rd General Meeting of the KCS